LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

TPS4631 Background: High-risk NMIBC is generally treated with adjuvant intravesical Bacille Calmette-Guérin (BCG). However, ~50% of patients experience recurrence and/or progression afterwards and are considered unresponsive. Detalimogene voraplasmid (EG-70) is an investigational, non-viral, non-integrating, intravesically administered gene therapy designed to elicit local stimulation of anti-tumor immune responses in the bladder and drive durable efficacy in NMIBC, while mitigating the risk of systemic toxicities from immune stimulation. The Phase 1 (dose-escalation) portion of the first-in-human Phase 1/2, open-label, multicenter study (LEGEND; NCT04752722) of detalimogene voraplasmid is complete. The Phase 2 dose was identified, treatment was generally well tolerated, with an overall complete response (CR) rate of 73% [Kalota S, et al. AUA 2024]. Herein, we describe the ongoing Phase 2 portion of the study, which opened to enrollment in May 2023, which recently added a new cohort of BCG-unresponsive HG Ta/T1 papillary only (no carcinoma in situ [CIS]) disease. Methods: Eligibility criteria: age ≥18 years; ECOG PS 0−2; NMIBC, with/without resected coexisting papillary tumors, ineligible for, or elected not to undergo, cystectomy; satisfactory bladder function. Patients receive detalimogene voraplasmid 0.8 mg/mL in 50 mL (intravesical administration, Weeks 1, 2, 5 & 6, 12-week cycle) for 4 cycles, and patients with CR at the end of the 4 th cycle will enter maintenance treatment to receive 2 instillations per cycle (at Weeks 1 and 2) for up to another 8 cycles: BCG-unresponsive with CIS (Cohort 1); BCG-naïve with CIS (Cohort 2A) or BCG-exposed with CIS (Cohort 2B); BCG-unresponsive NMIBC with high-grade papillary disease without CIS (Cohort 3). Phase 2 primary endpoints: efficacy (CR rate at Week 48); safety. Secondary endpoints: progression-free survival; CR rate at Weeks 12, 24, 36, and 48; duration of response. The study is being conducted in accordance with the ethical principles of the Declaration of Helsinki and is consistent with ICH/GCP. All patients provide written informed consent. The Phase 2 portion of the study is enrolling and will recruit approximately 300 patients across all cohorts, from sites in the USA, Canada, Europe, and the Asia-Pacific region. Clinical trial information: NCT04752722 .

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.tps4631
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

John Arthur Taylor, Raj Pruthi, Shreyas Joshi, Gautam Jayram et al.
Journal of Clinical Oncology
Bladder and Urothelial Cancer Treatments
article

LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

John Arthur Taylor, Raj Pruthi, Shreyas Joshi, Gautam Jayram, Wassim Kassouf, Raj Satkunasivam, Karina Chan, Ashish M. Kamat, Yair Lotan, Christine Tosone, Gary D. Steinberg, Scott Johnson, Christine Ibilibor, Anne Schuckman, Anthony Cheung, Jen‐Jane Liu, Vignesh T. Packiam, Neal D. Shore, Sam S. Chang, Rian J. Dickstein
article en

Abstract

TPS4631 Background: High-risk NMIBC is generally treated with adjuvant intravesical Bacille Calmette-Guérin (BCG). However, ~50% of patients experience recurrence and/or progression afterwards and are considered unresponsive. Detalimogene voraplasmid (EG-70) is an investigational, non-viral, non-integrating, intravesically administered gene therapy designed to elicit local stimulation of anti-tumor immune responses in the bladder and drive durable efficacy in NMIBC, while mitigating the risk of systemic toxicities from immune stimulation. The Phase 1 (dose-escalation) portion of the first-in-human Phase 1/2, open-label, multicenter study (LEGEND; NCT04752722) of detalimogene voraplasmid is complete. The Phase 2 dose was identified, treatment was generally well tolerated, with an overall complete response (CR) rate of 73% [Kalota S, et al. AUA 2024]. Herein, we describe the ongoing Phase 2 portion of the study, which opened to enrollment in May 2023, which recently added a new cohort of BCG-unresponsive HG Ta/T1 papillary only (no carcinoma in situ [CIS]) disease. Methods: Eligibility criteria: age ≥18 years; ECOG PS 0−2; NMIBC, with/without resected coexisting papillary tumors, ineligible for, or elected not to undergo, cystectomy; satisfactory bladder function. Patients receive detalimogene voraplasmid 0.8 mg/mL in 50 mL (intravesical administration, Weeks 1, 2, 5 & 6, 12-week cycle) for 4 cycles, and patients with CR at the end of the 4 th cycle will enter maintenance treatment to receive 2 instillations per cycle (at Weeks 1 and 2) for up to another 8 cycles: BCG-unresponsive with CIS (Cohort 1); BCG-naïve with CIS (Cohort 2A) or BCG-exposed with CIS (Cohort 2B); BCG-unresponsive NMIBC with high-grade papillary disease without CIS (Cohort 3). Phase 2 primary endpoints: efficacy (CR rate at Week 48); safety. Secondary endpoints: progression-free survival; CR rate at Weeks 12, 24, 36, and 48; duration of response. The study is being conducted in accordance with the ethical principles of the Declaration of Helsinki and is consistent with ICH/GCP. All patients provide written informed consent. The Phase 2 portion of the study is enrolling and will recruit approximately 300 patients across all cohorts, from sites in the USA, Canada, Europe, and the Asia-Pacific region. Clinical trial information: NCT04752722 .

Journal of Clinical OncologyVol. 43(16_suppl)
Rutgers, The State University of New Jersey (US), University of Southern California (US), University of Maryland, Baltimore (US), Rush University Medical Center (US), Houston Methodist (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), Oregon Health & Science University (US), Medical College of Wisconsin (US), Cornell University (US), McGill University Health Centre (CA), Southwestern Medical Center (US), Urology Associates (US), Methodist Hospital (US), University of Kansas Medical Center (US), Klogene (United States) (US), Carolina Urologic Research Center (US), Southwestern Medical Center (US), University of Virginia (US), The University of Texas Southwestern Medical Center (US), Vanderbilt University Medical Center (US)
Openalex Percentile: Top 79%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.